Larimar Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
LRMR Nasdaq 2836 larimartx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Larimar Therapeutics, Inc.

Larimar: Q3 Earnings Snapshot - Nov 5th, 2025 5:14 am
Larimar Therapeutics Reports Third Quarter 2025 Financial Results - Nov 5th, 2025 5:00 am
Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Oct 4th, 2025 7:27 am
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia - Sep 29th, 2025 5:00 am
Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia - Sep 28th, 2025 3:00 pm
Larimar: Q2 Earnings Snapshot - Aug 14th, 2025 5:13 am
Larimar Therapeutics Reports Second Quarter 2025 Financial Results - Aug 14th, 2025 5:00 am
With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest - Aug 10th, 2025 7:45 am
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Jul 31st, 2025 2:15 pm
Larimar Therapeutics Announces Pricing of Underwritten Public Offering - Jul 29th, 2025 9:50 pm
Larimar Therapeutics Announces Proposed Underwritten Public Offering - Jul 29th, 2025 2:01 pm
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Jul 17th, 2025 7:11 am
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - Jul 16th, 2025 7:01 am
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia - Jul 8th, 2025 5:00 am
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program - Jun 23rd, 2025 5:00 am
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia - Jun 20th, 2025 2:05 pm
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - May 21st, 2025 9:22 am
Larimar Therapeutics Reports First Quarter 2025 Financial Results - Apr 30th, 2025 5:00 am
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Mar 28th, 2025 8:34 am
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Mar 24th, 2025 5:00 am